| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 1,575.000 +4.95% on 04/19/24 | | 1,713.000 -3.50% on 03/28/24 | -44.800 (-2.64%) since 03/26/24 |
| 3-Month | 1,514.800 +9.12% on 01/31/24 | | 1,719.800 -3.88% on 03/07/24 | +116.000 (+7.55%) since 01/26/24 |
| 52-Week | 1,302.600 +26.90% on 07/11/23 | | 1,719.800 -3.88% on 03/07/24 | +210.800 (+14.62%) since 04/26/23 |
These companies are close to launching new products that could supercharge revenue.
U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus
/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...
While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive 12-month findings from the SOLAR study. SOLAR is the first head-to-head,...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts from the company’s diverse portfolio...
| 3rd Resistance Point | 1,682.515 |
| 2nd Resistance Point | 1,669.007 |
| 1st Resistance Point | 1,661.004 |
| Last Price | 1,653.000 |
| 1st Support Level | 1,639.493 |
| 2nd Support Level | 1,625.985 |
| 3rd Support Level | 1,617.982 |
| 52-Week High | 1,719.800 |
| Last Price | 1,653.000 |
| Fibonacci 61.8% | 1,560.430 |
| Fibonacci 50% | 1,511.200 |
| Fibonacci 38.2% | 1,461.970 |
| 52-Week Low | 1,302.600 |